active
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AMEN BROTHER.....
Rockwell Medical, Inc. Receives FDA Approval for Triferic® AVNU (Ferric Pyrophosphate Citrate), Intravenous Formulation of Triferic for Replacement of Iron and Maintenance of Hemoglobin in Hemodialysis Patients
https://finance.yahoo.com/news/rockwell-medical-inc-receives-fda-152154174.html
Rockwell Medical, Inc. Receives FDA Approval for Triferic® AVNU (Ferric Pyrophosphate Citrate), Intravenous Formulation of Triferic for Replacement of Iron and Maintenance of Hemoglobin in Hemodialysis Patients
https://finance.yahoo.com/news/rockwell-medical-inc-receives-fda-152154174.html
Right now... NEWS OUT!!!
JUST bought into RMTI Short term play...... THEY HAVE A FDA PDUFA decision TOMORROW!
JUST bought into RMTI stands a GREAT chance of being approved because the drug has already been FDA approved for a similar problem!
JUST GOT IN@2.42
Aquestive Therapeutics
Market value: $116.5 million
TipRanks consensus price target: $17.00 (383% upside potential)
TipRanks consensus rating: Strong Buy
Aquestive Therapeutics' (AQST, $3.52) patented PharmFilm technology offers an effective drug delivery method that can be customized to meet the specific absorption, bioavailability and onset of action requirements. And following the company's preliminary fourth-quarter earnings release, in which it provided its first-time 2020 outlook, analysts remain with two feet on board.
Writing for RBC Capital, Randall Stanicky notes that while the guidance came in lower than he expected, he believes management is being conservative. Specifically, he points out that the company excluded contributions from Libervant, which will most likely go up for approval in late September, and said Parkinson's Disease treatment APL-130277 will only contribute a Q4 milestone payment.
Based on this development, Stanicky writes, "Our new estimates reflect these revisions though we see potential for numbers to move higher pending further visibility on Libervant launch timing and expectations."
"Overall, while our numbers have been revised modestly lower, our fundamental view of the story is unchanged; 2020 is set to be an inflection year with several updates that can drive the stock higher including anticipated approval of key value driver Libervant," continues Stanicky, who has an Outperform rating and $9 price target on AQST shares.
Stanicky's price target is the most conservative among analysts who have sounded off on this low-priced stock during the past three months. Three other Buy calls have included $10, $13 and even $36 targets, averaging out to a consensus PT of $17, or more than 380% upside over the next 52 weeks.
This site let me see the potential, so I’m interested!!!
Click on DRUG INFORMATION to see what i saw!!
https://www.biopharmcatalyst.com/company/AQST
UP A LITTLE IN AH... LOVE IT!
NBRV UP 25%!!!
Thanks!!!
1st time noticing this stock, potential looking GREAT, any thoughts on financials?
If you would click on DRUG INFORMATIOM
https://www.biopharmcatalyst.com/company/AQST
NORETREAT... can you do me a favor?
If so please take a look at AQST, need honest feedback please.
Started buying since 2.39 got my average down to 1.22!
Order taken@.51
For Nabriva Therapeutics PLC (NASDAQ: NBRV), Morgan Stanley downgraded the stock from Overweight to Equal-Weight. For the fourth quarter, Nabriva Therapeutics had an EPS of ($0.29), compared to year-ago quarter EPS of ($0.46). The stock has a 52-week-high of $3.27 and a 52-week-low of $0.50. Nabriva Therapeutics's stock last closed at $0.63 per share.
1y Target Est 4.67
For Nabriva Therapeutics PLC (NASDAQ: NBRV), Morgan Stanley downgraded the stock from Overweight to Equal-Weight. For the fourth quarter, Nabriva Therapeutics had an EPS of ($0.29), compared to year-ago quarter EPS of ($0.46). The stock has a 52-week-high of $3.27 and a 52-week-low of $0.50. Nabriva Therapeutics's stock last closed at $0.63 per share.
GREAT MOVE, don’t stay awak too long!
CONGRATS, wish I would have done the same... maybe tomorrow!
I picked up a few shares @64... WAS GREEDY EARLIER WITH A .45 ORDER IN
As of December 31, 2019, Nabriva Therapeutics had $86.0 million in cash and cash equivalents, compared to $102.0 million as of December 31, 2018.
Based on its current operating plans, immediately following the Prepayment, the Company expects that its existing cash resources and anticipated net product sales revenues, will be sufficient to enable Nabriva to fund its operating expenses, debt service obligations and capital expenditure requirements into the third quarter of 2020. This estimate assumes that Nabriva’s NDA for CONTEPO is approved on the PDUFA action date and that it remains in compliance with the covenants under its Loan Agreement.
Please refer to the Annual Report on Form 10-K of Nabriva Therapeutics for the fiscal year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission, for additional information regarding the Company’s business and financial results.
Great news!
Thanks for the input!
TIP..............
Also bought 10k 0f NBRV@.57 got 1 drug approved last yr. and one due FDA approval in June 2020
Closed THURSDAY 1.02... SOMEONE DUMPED Friday, don’t really know why but worth the risk IMHO
HERE’S THE FINANCIALS
Balance Sheet
Total Cash (mrq) 86.19M
Total Cash Per Share (mrq) 1.07
Total Debt (mrq) 34.5M
Total Debt/Equity (mrq) 83.59
Current Ratio (mrq) 5.48
Book Value Per Share (mrq) 0.51
1y Target Est 7.00
52 Week Range 0.5100 - 3.2700
Share Statistics
Avg Vol (3 month) 3 1.58M
Avg Vol (10 day) 3 2.45M
Shares Outstanding 5 94.55M
Float 79.65M
% Held by Insiders 1 1.24%
% Held by Institutions 1 43.40%
Shares Short (Feb 28, 2020) 4 5.48M
Short Ratio (Feb 28, 2020) 4 5.35
Short % of Float (Feb 28, 2020) 4 7.58%
Short % of Shares Outstanding (Feb 28, 2020) 4 5.79%
Good to hear,
I actually Figured you would be.
\\\\\\\\\
Did you notice the volume todat?
Got a feeling somebody needed to raise some cash... any thoughts?
Agreed one the BUY of 202!!!!!
Texting my accountant and everyone I know about this stock!!!!
1 year projected prince..
1y Target Est 7.00
Amen brother!
If it sinks more, BUYING MORE,l love the risk/reward ratio down here!
Here spare three Financials....
Balance Sheet
Total Cash (mrq) 86.19M
Total Cash Per Share (mrq) 1.07
Total Debt (mrq) 34.5M
Total Debt/Equity (mrq) 83.59
Current Ratio (mrq) 5.48
Book Value Per Share (mrq) 0.51
So while many are “SELLING” I will “KEEP BUYING”
Loaded up todat@4.33
I loaded up starting at .825 all the way down to 10k@.5689
Nabriva Therapeutics (nbrv)
Similarly to GMDA, Nabriva Therapeutics is a company that also has 2 premiere projects in the works and has a lot of promising developments going on. Nabriva's lead drug XENLETA, which treats patients with community-acquired bacterial pneumonia (CABP), recently won FDA approval and is being distributed in the U.S. since August. Nabriva also recently acquired Zvante Therapeutics and added CONTEPO to its portfolio; an injection for the treatment of complicated urinary tract infections. In contrast to XENLETA, however, CONTEPO has yet to gain FDA approval.
Northland analyst Carl Brynes is forecasting "peak global sales of XENLETA at $1B, supported by XENLETA's clinical differentiation and oral/IV dosing forms." With a market cap of only $130.58 million, the analyst sees huge upside for NBRV stock, as he reiterates an Outperform rating and $12.50 price target. (To watch Brynes' track record, click here)
Wedbush analyst Robert Driscoll added, "We see XENLETA’s profile as well suited for the treatment of CABP, given its favorable safety and efficacy profile, a narrow but CABP-targeted spectrum, and flexible IV to oral/oral dosing. Importantly, two Ph 3 studies have demonstrated efficacy with a short treatment course of 5-7 days, which we note aligns with antibiotic stewardship principles. With recent favorable changes to the reimbursement landscape and a clear plan in place for lefamulin commercialization, plus clarification around second asset CONTEPO NDA resubmission timelines, we believe NBRV shares are currently undervalued."
All in all, the drug maker is without question a Wall Street favorite, considering TipRanks analytics indicate NBRV as a Strong Buy. Out of 5 analysts polled in the last 3 months, all 5 are bullish on the stock. With a return potential of nearly 390%, the stock's consensus target price stands at $8.70.
Notice how these CROOKS(MM) DROPPED THE STOCK PRICE FOR A MOMENT TO STEAL STOP LOSS ORDERS YESTERDAY?
No short sellers!
Corruption!!!
Market Makers letting Institutions buy these cheap shares!!
Next week/month they will dump them on their clients(suckers)
BUYrecommendations coming from all of them!
Check out that volume Institutions loading up!
Everything for SALE IN THIS COUNTRY......
ASK MOSCOW NITCH
`
Nabriva Therapeutics' stock soars in heavy volume after FDA approves NDA for CABP treatment
MarketWatch
Tomi Kilgore
MarketWatchAugust 20, 2019
Shares of Nabriva Therapeutics PLC shot up 27% to pace the premarket gainers in active trading Tuesday, after the biotechnology company said its new drug application (NDA) for the oral and intravenous formulations of Xenleta, a treatment for community-acquired bacteria pneumonia, was approved by the Food and Drug Administration. Trading volume of over 1.3 million shares was already more than the full-day average of about 922,000 shares. "Today's approval of XENLETA is a significant breakthrough in the collective fight against the growing threat of antimicrobial resistance and provides a desperately needed IV and oral empiric monotherapy treatment option for adults with CABP," said Chief Executive Ted Schroeder. The company expects Xenleta to be available in mid-September through U.S. specialty distributors, and will have a wholesale acquisition price of $205 per IV patient treatment day and $275 per oral patient treatment day. The stock has slumped 7.5% over the past three months through Monday, while the S&P 500 has gained 2.9%.
https://finance.yahoo.com/m/030eca16-3952-3a54-8d2d-20c7f3467fe7/nabriva-therapeutics%26%2339%3B.html
Hopefully RDHL will be my 3rd winner this year!!!
Hopefully RDHL WILL BE MY 3rd winner this year!!!
HOPEFULLY SOME ANALYST UPGRADES IN THE A.M.!!!